Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000464034 | SCV000545984 | uncertain significance | Baller-Gerold syndrome | 2024-12-08 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 751 of the RECQL4 protein (p.Arg751Gln). This variant is present in population databases (rs559066300, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with RECQL4-related conditions. ClinVar contains an entry for this variant (Variation ID: 407010). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt RECQL4 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000766011 | SCV000897443 | uncertain significance | Baller-Gerold syndrome; Rapadilino syndrome; Rothmund-Thomson syndrome | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV003237855 | SCV002009917 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002523304 | SCV003696338 | uncertain significance | Inborn genetic diseases | 2021-09-01 | criteria provided, single submitter | clinical testing | The c.2252G>A (p.R751Q) alteration is located in exon 14 (coding exon 14) of the RECQL4 gene. This alteration results from a G to A substitution at nucleotide position 2252, causing the arginine (R) at amino acid position 751 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003237855 | SCV004236571 | uncertain significance | not provided | 2023-06-12 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV003237855 | SCV005196232 | uncertain significance | not provided | criteria provided, single submitter | not provided |